US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big ga

MBX Biosciences (NASDAQ: MBX - Get Free Report) and Lakewood-Amedex Biotherapeutics (NASDAQ: LABT -

Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 56.1% to $4.62 during Monday's after-

MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discov

CARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq:

I initiate MBX Biosciences with a speculative buy, anchored by Canvuparatide's de-risked clinical pr

MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once

MBX Biosciences Inc. (NASDAQ:MBX) on Thursday reported full results from its 12-week Avail Phase 2 t

MBX Biosciences reported one-year canvuparatide data showing sustained calcium control and progress

US stock futures rise, Dow futures up 300 points. Lennar Corp falls after reporting mixed Q2 results

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Pha

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Pha

CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stag

MBX Biosciences, a clinical-stage biotech developing peptide therapies, reported a notable insider s

CARMEL, Ind. and BURLINGTON, Mass.

Microbix Biosystems Inc. (MBX:CA) Q2 2026 Earnings Call Transcript

Barclays analyst Eliana Merle maintains MBX Biosciences (NASDAQ:MBX) with a Overweight and raises

Citizens analyst Jonathan Wolleben maintains MBX Biosciences (NASDAQ:MBX) with a Market Outperfor

MBX Biosciences, Inc. (MBX) Discusses Novel Approaches and Clinical Progress in Obesity Therapeutics

MBX Biosciences NASDAQ: MBX used its Obesity Day event to outline preliminary clinical data for its

Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy

Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%

Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%

MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.51) per share which beat the analyst c

Results from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in Ju

Results Release and Webinar Discussion on Morning of May 14, 2026 MISSISSAUGA, ON / ACCESS Newswire

CARMEL, Ind. and BURLINGTON, Mass.

These relatively small biotechs have recent catalysts that haven't yet been fully priced into their

MISSISSAUGA, ON / ACCESS Newswire / April 27, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF,

CARMEL, Ind. and BURLINGTON, Mass.

Releasing Episodes of Season Two of "Diagnostics: Beyond the Lab" Podcast MISSISSAUGA, ON / ACCESS N

MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.49) per share which beat the analyst c

Barclays analyst Eliana Merle initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Overweigh

Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises

UBS analyst Michael Yee initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating and

Stifel analyst Annabel Samimy maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the pr

Goldman Sachs analyst Corinne Johnson initiates coverage on MBX Biosciences (NASDAQ:MBX) with a S

Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and lowers

MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.63) per share which beat the analyst c